Logo image of NVO

NOVO-NORDISK A/S-SPONS ADR (NVO) Stock Price, Quote, News and Overview

NYSE:NVO - New York Stock Exchange, Inc. - US6701002056 - ADR - Currency: USD

68.2  +1.18 (+1.76%)

After market: 68.1885 -0.01 (-0.02%)

NVO Quote, Performance and Key Statistics

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (5/20/2025, 8:21:50 PM)

After market: 68.1885 -0.01 (-0.02%)

68.2

+1.18 (+1.76%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High148.15
52 Week Low57
Market Cap302.74B
Shares4.44B
Float4.17B
Yearly Dividend1.49
Dividend Yield2.62%
PE19.6
Fwd PE13.57
Earnings (Next)08-06 2025-08-06/bmo
IPO05-17 1974-05-17


NVO short term performance overview.The bars show the price performance of NVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

NVO long term performance overview.The bars show the price performance of NVO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of NVO is 68.2 USD. In the past month the price increased by 13.84%. In the past year, price decreased by -49.87%.

NOVO-NORDISK A/S-SPONS ADR / NVO Daily stock chart

NVO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 54.29 708.16B
JNJ JOHNSON & JOHNSON 15.29 369.72B
NVS NOVARTIS AG-SPONSORED ADR 13.51 221.76B
AZN ASTRAZENECA PLC-SPONS ADR 18.8 216.78B
MRK MERCK & CO. INC. 10.01 196.20B
PFE PFIZER INC 7.33 133.39B
SNY SANOFI-ADR 13.85 129.48B
BMY BRISTOL-MYERS SQUIBB CO 6.52 97.42B
GSK GSK PLC-SPON ADR 6.99 77.70B
ZTS ZOETIS INC 27.18 73.00B
HLN HALEON PLC-ADR 22.49 49.69B
TAK TAKEDA PHARMACEUTIC-SP ADR 26.43 44.91B

About NVO

Company Profile

NVO logo image Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880 DK

CEO: Lars Fruergaard Jorgensen

Employees: 76826

NVO Company Website

NVO Investor Relations

Phone: 4544448888

NOVO-NORDISK A/S-SPONS ADR / NVO FAQ

What is the stock price of NOVO-NORDISK A/S-SPONS ADR today?

The current stock price of NVO is 68.2 USD. The price increased by 1.76% in the last trading session.


What is the ticker symbol for NOVO-NORDISK A/S-SPONS ADR stock?

The exchange symbol of NOVO-NORDISK A/S-SPONS ADR is NVO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is NVO stock listed?

NVO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for NOVO-NORDISK A/S-SPONS ADR stock?

32 analysts have analysed NVO and the average price target is 103.72 USD. This implies a price increase of 52.09% is expected in the next year compared to the current price of 68.2. Check the NOVO-NORDISK A/S-SPONS ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NOVO-NORDISK A/S-SPONS ADR worth?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a market capitalization of 302.74B USD. This makes NVO a Mega Cap stock.


How many employees does NOVO-NORDISK A/S-SPONS ADR have?

NOVO-NORDISK A/S-SPONS ADR (NVO) currently has 76826 employees.


What are the support and resistance levels for NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a resistance level at 68.26. Check the full technical report for a detailed analysis of NVO support and resistance levels.


Is NOVO-NORDISK A/S-SPONS ADR (NVO) expected to grow?

The Revenue of NOVO-NORDISK A/S-SPONS ADR (NVO) is expected to grow by 19.4% in the next year. Check the estimates tab for more information on the NVO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NOVO-NORDISK A/S-SPONS ADR (NVO) stock pay dividends?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a dividend yield of 2.62%. The yearly dividend amount is currently 1.49. Check the full fundamental report for a detailed analysis of NVO dividend history, reliability and sustainability.


When does NOVO-NORDISK A/S-SPONS ADR (NVO) report earnings?

NOVO-NORDISK A/S-SPONS ADR (NVO) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of NOVO-NORDISK A/S-SPONS ADR (NVO)?

The PE ratio for NOVO-NORDISK A/S-SPONS ADR (NVO) is 19.6. This is based on the reported non-GAAP earnings per share of 3.48 and the current share price of 68.2 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVO.


What is the Short Interest ratio of NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

The outstanding short interest for NOVO-NORDISK A/S-SPONS ADR (NVO) is 0.6% of its float. Check the ownership tab for more information on the NVO short interest.


NVO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to NVO. When comparing the yearly performance of all stocks, NVO is a bad performer in the overall market: 90.13% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NVO Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to NVO. NVO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVO Financial Highlights

Over the last trailing twelve months NVO reported a non-GAAP Earnings per Share(EPS) of 3.48. The EPS increased by 15.52% compared to the year before.


Industry RankSector Rank
PM (TTM) 34.78%
ROA 21.68%
ROE 70.38%
Debt/Equity 0.62
Chartmill High Growth Momentum
EPS Q2Q%6.42%
Sales Q2Q%10.71%
EPS 1Y (TTM)15.52%
Revenue 1Y (TTM)25.03%

NVO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to NVO. The Buy consensus is the average rating of analysts ratings from 32 analysts.

For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 19.4% for NVO


Ownership
Inst Owners37.62%
Ins OwnersN/A
Short Float %0.6%
Short Ratio2.64
Analysts
Analysts74.38
Price Target103.72 (52.08%)
EPS Next Y19.72%
Revenue Next Year19.4%